Osaic Holdings’s InVivo Therapeutics Holdings Corp NVIV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-5
| Closed | -$3 | – | 7555 |
|
|
2023
Q4 | $3 | Sell |
5
-1
| -17% | -$1 | ﹤0.01% | 7267 |
|
|
2023
Q3 | $6 | Sell |
6
-1
| -14% | -$1 | ﹤0.01% | 7351 |
|
|
2023
Q2 | $8 | Hold |
7
| – | – | ﹤0.01% | 7414 |
|
|
2023
Q1 | $7 | Hold |
7
| – | – | ﹤0.01% | 7461 |
|
|
2022
Q4 | $0 | Hold |
7
| – | – | ﹤0.01% | 7776 |
|
|
2022
Q3 | $0 | Hold |
7
| – | – | ﹤0.01% | 7814 |
|
|
2022
Q2 | $0 | Buy |
7
+3
| +75% | +$16 | ﹤0.01% | 7896 |
|
|
2022
Q1 | $0 | Hold |
4
| – | – | ﹤0.01% | 7841 |
|
|
2021
Q4 | $0 | Hold |
4
| – | – | ﹤0.01% | 7879 |
|
|
2021
Q3 | $0 | Sell |
4
-1
| -20% | -$16 | ﹤0.01% | 7561 |
|
|
2021
Q2 | $0 | Buy |
5
+4
| +400% | +$76 | ﹤0.01% | 7348 |
|
|
2021
Q1 | $0 | Hold |
1
| – | – | ﹤0.01% | 7140 |
|
|
2020
Q4 | $0 | Hold |
1
| – | – | ﹤0.01% | 6808 |
|
|
2020
Q3 | $0 | Hold |
1
| – | – | ﹤0.01% | 6623 |
|
|
2020
Q2 | $0 | Sell |
1
-30
| -97% | -$1.17K | ﹤0.01% | 6568 |
|
|
2020
Q1 | $1K | Buy |
+31
| New | +$4.39K | ﹤0.01% | 6017 |
|
Other funds holding NVIV
Osaic Holdings's NVIV Position: Q1 2024 in Review
Osaic Holdings sold out of InVivo Therapeutics Holdings Corp (NVIV) in Q1 2024, closing a stake of 5 shares — an estimated $3 sold.
Osaic Holdings first reported a position in NVIV in Q1 2020 and held it in 16 quarters. The position peaked at $1K in Q1 2020. 4 funds tracked by Wall St. Rank hold NVIV as of Q1 2024.
- Osaic Holdings reported no remaining InVivo Therapeutics Holdings Corp position as of Q1 2024 after selling out during the quarter.
- Osaic Holdings sold 5 InVivo Therapeutics Holdings Corp shares in Q1 2024, an estimated $3.
- Osaic Holdings first reported a position in InVivo Therapeutics Holdings Corp in Q1 2020 and held it in 16 quarters.
- Osaic Holdings's InVivo Therapeutics Holdings Corp position peaked at $1K in Q1 2020.
- 4 funds tracked by Wall St. Rank held InVivo Therapeutics Holdings Corp as of Q1 2024.
Based on Osaic Holdings's 13F filing for Q1 2024, filed 10 May 2024.